Beth Delambo
Psychiatric/Mental Health · Indianapolis, INNPI 1568775153
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 496 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,827, 3.8 times the $479 reported in 2021. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 496 payments — averaging $14.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$703
- AbbVie$625
- Otsuka America Pharmaceutical, Inc.$585
- Corium, LLC$538
- Johnson & Johnson$498
- plus $3K from 18 others
What the payments were for
- Food & beverage$6,945100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 85 | $1,006 |
| Alkermes, Inc. | 13 | $703 |
| AbbVie | 45 | $625 |
| Otsuka America Pharmaceutical, Inc. | 46 | $585 |
| Corium, LLC | 37 | $538 |
| Johnson & Johnson | 38 | $498 |
| Supernus Pharmaceuticals, Inc. | 48 | $389 |
| Ironshore Pharmaceuticals Inc. | 22 | $316 |
| Tris Pharma Inc | 21 | $282 |
| Collegium Pharmaceutical, Inc. | 22 | $276 |
| Axsome Therapeutics, Inc. | 23 | $261 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $240 |
| Neurocrine Biosciences, Inc. | 19 | $235 |
| Lundbeck LLC | 12 | $218 |
| Bausch Health US, LLC | 17 | $199 |
| Noven Therapeutics, LLC | 7 | $136 |
| Vanda Pharmaceuticals Inc. | 6 | $119 |
| Neos Therapeutics, LP | 5 | $88 |
| Teva Pharmaceuticals USA, Inc. | 5 | $76 |
| Idorsia Pharmaceuticals US Inc | 4 | $60 |
| Almatica Pharma LLC | 2 | $35 |
| Merck | 2 | $34 |
| Biogen | 1 | $23 |
| Indivior Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,169
- LYBALVI$754
- ARISTADA INITIO$243
How this compares
$6,960 in reported general payments places this provider in the 90th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clonazepam | 35 | $209 |
| Alprazolam | 11 | $51 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Indianapolis
- Sonya RuedlingerIndianapolis$134K
- Devan GravesIndianapolis$12K
- Clyde YanIndianapolis$9K
- Olga Marie JiodioIndianapolis$6K
- Lindsay RussellIndianapolis$5K
- Nina VoigtIndianapolis$5K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Trina GreenwaldMarion$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.